<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="90449">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01927562</url>
  </required_header>
  <id_info>
    <org_study_id>C-10000</org_study_id>
    <nct_id>NCT01927562</nct_id>
  </id_info>
  <brief_title>Initial Clinical Evaluation of an Endoscopic Therapy for Type 2 Diabetes</brief_title>
  <official_title>Evaluation of the Fractyl Duodenal Remodeling System for the Treatment of Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fractyl Laboratories, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fractyl Laboratories, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and feasibility of the Fractyl Duodenal
      Remodeling System for the treatment of patients with poorly controlled Type 2 Diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Event Profile</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Type II Diabetes</condition>
  <arm_group>
    <arm_group_label>Duodenal Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fractyl Duodenal Remodeling System</intervention_name>
    <arm_group_label>Duodenal Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants Age &gt; 28 years and â‰¤ 75 years

          -  Male or Female

          -  Participants who have signed an informed consent form

        Exclusion Criteria:

          -  Participants diagnosed with Type I Diabetes or with a history of ketoacidosis

          -  Participants with an active systemic infection

          -  Participant with a known diagnosis or pre-existing symptoms of systemic lupus
             erythematosus, scleroderma or other autoimmune connective tissue disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>28 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eric Bannon</last_name>
    <phone>781-902-8812</phone>
    <email>eric@fractyl.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>INDISA</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Leonardo Rodriguez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 11, 2016</lastchanged_date>
  <firstreceived_date>August 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
